BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/30/2026 1:35:08 PM | Browse: 63 | Download: 273
 |
Received |
|
2026-02-02 03:05 |
|
Peer-Review Started |
|
2026-02-02 03:05 |
|
First Decision by Editorial Office Director |
|
2026-02-06 10:49 |
|
Return for Revision |
|
2026-02-06 10:49 |
|
Revised |
|
2026-02-19 11:08 |
|
Publication Fee Transferred |
|
2026-02-24 05:53 |
|
Second Decision by Editor |
|
2026-03-13 02:43 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-13 06:35 |
|
Articles in Press |
|
2026-03-13 06:35 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-24 07:22 |
|
Publish the Manuscript Online |
|
2026-06-30 13:35 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
CRAPT-M: An effective prognostic predictor for hepatocellular carcinoma patients treated with locoregional-bevacizumab-immunotherapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ze-Hao Zheng, Rui Xiao, Na Liu, Ben-Yi He, Wei Yu, Zhong-Shi Wu, Min-Shan Chen, Jie Mei, Dan-Dan Hu and Rong-Ping Guo |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the National Science and Technology Major Project of China |
2024ZD0520402 |
| Science and Technology Planning Project of Guangzhou |
2023A03J0601 |
|
| Corresponding Author |
Rong-Ping Guo, Department of Hepatobiliary Oncology,, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, Peoples Republic of China., Guangzhou 510060, Guangdong Province, China. guorp@sysucc.org.cn |
| Key Words |
Hepatocellular carcinoma; Bevacizumab; Checkpoint inhibitors; Hepatic arterial infusion chemotherapy; C reactive protein; Overall survival |
| Core Tip |
This study validated the prognostic value of the CRAPT-M model in patients with hepatocellular carcinoma receiving locoregional-bevacizumab-immunotherapy. The model effectively stratified overall survival and progression-free survival not only in the locoregional plus atezolizumab plus bevacizumab group but also in the locoregional plus sintilimab plus bevacizumab group. In addition, we developed a Simple-CRAPT-M model based on the number of risk factors, which may provide a more convenient tool for rapid risk stratification in clinical practice. |
| Publish Date |
2026-06-30 13:35 |
| Citation |
Zheng ZH, Xiao R, Liu N, He BY, Yu W, Wu ZS, Chen MS, Mei J, Hu DD, Guo RP. CRAPT-M: An effective prognostic predictor for hepatocellular carcinoma patients treated with locoregional-bevacizumab-immunotherapy. World J Gastroenterol 2026; 32(25): 119588
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i25/119588.htm |
| DOI |
https://doi.org/10.3748/wjg.119588 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
